A dose-finding study of aspirin for chemoprevention utilizing rectal mucosal prostaglandin E2levels as a biomarker

Cancer Epidemiology Biomarkers and Prevention

Volumn 11, Issue 3, 2002, Pages 275-279

  Sample, Dory ^a   Wargovich, Michael ^a   Fischer, Susan M ^a   Inamdar, Nikil ^b   Schwartz, Peter ^b   Wang, Xuemei ^a   Do, Kim Anh ^a   Sinicrope, Frank A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MacGregor Medical Association   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BIOLOGICAL MARKER; PROSTAGLANDIN; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE;

ADENOMA; ADULT; AGED; ARTICLE; CANCER PREVENTION; CLINICAL TRIAL; COLORECTAL CANCER; COLORECTAL TUMOR; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG INDUCED DISEASE; DRUG MECHANISM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; PROTECTION; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; AGED, 80 AND OVER; ASPIRIN; CHEMOPREVENTION; COLORECTAL NEOPLASMS; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTESTINAL MUCOSA; MALE; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL;

EID: 0036227319     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Cancer statistics, 2000
2. Aspirin use and reduced risk of fatal colon cancer
3. Reduced risk of large-bowel adenomas among aspirin users
4. Aspirin use and the risk of colorectal cancer and adenoma in male health professionals
5. Aspirin and the risk of colorectal cancer in women
6. Aspirin use and colorectal cancer: Post-trial follow-up data from the Physician's Health Study
7. Low-dose aspirin and incidence of colorectal tumors in a randomized trial
8. Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats
9. Chemoprevention of spontaneous intestinal adenomas in the ApcMin mouse model by the nonsteroidal anti-inflammatory drug piroxicam
10. Colorectal cancer prevention and treatment
11. Prostaglandin endoperoxide synthase: Why two isoforms?
12. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas
13. Expression of cyclooxygenase-1 and -2 in human colorectal cancer
14. Reduced expression of cyclooxygenase 2 proteins in hereditary nonpolyposis colorectal cancers relative to sporadic cancers
15. 2in human colon cancer cells
16. The role of cyclooxygenase inhibition in the antineoplastic effects of nonsteroidal anti-inflammatory drugs (NSAIDs)
17. Cyclooxygenase regulates angiogenesis induced by colon cancer cells
18. PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs
19. Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity?
20. Final report on the aspirin component of the ongoing Physicians' Health Study
21. Comparison of upper gastrointestinal toxicity of Rofecoxib and Naproxen in patients with rheumatoid arthritis
22. Events associated with mouse skin tumor promotion with respect to arachidonic acid metabolism: A comparison between SENCAR and NMRI mice
23. Minimization of salicylic acid formation during preparation of aspirin products for analysis by high-performance liquid chromatography
24. Improved liquid-chromatography of aspirin, salicylate, and salicyluric acid in plasma, with a modification for determining aspirin metabolites in urine
25. Suppression of human colorectal mucosal prostaglandins: Determining the lowest effective aspirin dose
26. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons
27. Recruiting high risk women into a breast cancer health promotion trial
28. Post-study aspirin intake and factors motivating participation in a colorectal cancer chemoprevention trial